Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies
Psychiatry Investigation · 25.02.2026 · 23 (2) · 183-200
DOI: 10.30773/pi.2025.0400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry Investigation, erschienen am 25.02.2026. Verfasst von Hyun Woong Roh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korean Association for Geriatric Psychiatry, National Research Foundation of Korea, Ministry of Science and ICT.
Themen: Demenz
Abstract (Originalsprache)
Objective
This review overviewed the recent paradigm shifts in the diagnosis and management of Alzheimer’s disease (AD), emphasizing the 2024 Alzheimer’s Association (AA) revised criteria, advances in cerebrospinal fluid (CSF) and blood-based biomarkers (BBMs), and practical considerations for anti-amyloid monoclonal antibody therapy.
Methods
We conducted a narrative appraisal of consensus frameworks (2018 National Institute on Aging–Alzheimer’s Association [NIA-AA] amyloid, tau, and neurodegeneration [AT(N)] and the 2024 AA criteria), clinical practice guidance from AA released in 2025, regulatory status of CSF and BBMs. Intended-use settings (triage vs. confirmatory) of BBMs and implementation of anti-amyloid anti-body treatments (lecanemab or donanemab) in real-world practice in Korea were also reviewed.
Results
The 2024 AA criteria define AD biologically and designate A and T as core biomarkers; Core 1 biomarkers can establish AD irrespective of symptoms, whereas Core 2 biomarkers refine staging. A two-cutoff BBM strategy (positive/intermediate/negative) reduces misclassification and guides confirmatory CSF/positron emission tomography (PET) or retesting. BBMs now approach CSF/PET accuracy for amyloid detection, enable triage and, in selected settings, confirmation, and show utility for monitoring treatment response. Integration of clinical stages (1–6) with biological stages (A–D) clarifies syndrome–pathology discordance. Special scenarios—maintenance after induction, APOE ε4 homozygotes, Down syndrome, and serious mental illness—require individualized risk–benefit assessment. In South Korea, constrained access to tau PET and some BBMs necessitates Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision–anchored evaluation with selective biomarker testing.
Conclusion
Biomarker-oriented diagnosis and anti-amyloid therapies are reshaping AD care. Priorities include rigorous validation of BBMs across populations, equitable access to core biomarkers, safety strategies, and real-world evidence to implement maintenance and special-population care pathways.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, Ajou University School of Medicine, Suwon, Republic of Korea.
- Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
- Department of Psychiatry, Institute of Behavioral Science in Medicine, Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Psychiatry, Seoul Metropolitan Government Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Republic of Korea.
- Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Förderung
- Korean Association for Geriatric Psychiatry
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Roh, H. W., Chang, Y. Y., Kim, K. Y., Jeon, S. Y., Wang, S. M., Kim, E., Bae, J. N., & Ryu, S. H. (2026). Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies. Psychiatry Investigation, 23(2), 183-200. https://doi.org/10.30773/pi.2025.0400
Vancouver
Roh HW, Chang YY, Kim KY, Jeon SY, Wang SM, Kim E, et al. Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies. Psychiatry Investigation. 2026;23(2):183-200. doi:10.30773/pi.2025.0400
BibTeX
@article{Roh2026,
author = {Roh, Hyun Woong and Chang, Yoon Young and Kim, Keun You and Jeon, So Yeon and Wang, Sheng-Min and Kim, Eosu and Bae, Jae-Nam and Ryu, Seung-Ho},
title = {Evolving Alzheimer’s Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies},
journal = {Psychiatry Investigation},
year = {2026},
volume = {23},
number = {2},
pages = {183--200},
doi = {10.30773/pi.2025.0400}
}
EUVIMED